Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Dose Escalation Study to Assess the Safety and Tolerability of Lapatinib in Combination With Carboplatin, Paclitaxel, With and Without Trastuzumab in Subjects With Metastatic Breast Cancer

Next Previous
Trial Profile

A Phase I, Dose Escalation Study to Assess the Safety and Tolerability of Lapatinib in Combination With Carboplatin, Paclitaxel, With and Without Trastuzumab in Subjects With Metastatic Breast Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Carboplatin; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; GSK; Novartis Pharmaceuticals

Most Recent Events

  • 06 Dec 2019 Status changed from active, no longer recruiting to completed.
  • 29 Aug 2019 Planned End Date changed from 28 Jun 2019 to 30 Sep 2019.
  • 14 May 2019 Planned End Date changed from 31 Dec 2019 to 28 Jun 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top